JP2022531387A5 - - Google Patents
Info
- Publication number
- JP2022531387A5 JP2022531387A5 JP2021564994A JP2021564994A JP2022531387A5 JP 2022531387 A5 JP2022531387 A5 JP 2022531387A5 JP 2021564994 A JP2021564994 A JP 2021564994A JP 2021564994 A JP2021564994 A JP 2021564994A JP 2022531387 A5 JP2022531387 A5 JP 2022531387A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- items
- composition according
- composition
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962842722P | 2019-05-03 | 2019-05-03 | |
| US62/842,722 | 2019-05-03 | ||
| PCT/US2020/030946 WO2020227062A1 (en) | 2019-05-03 | 2020-05-01 | Pharmaceutical formulations containing cd80 extracellular domain-fc fusion proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022531387A JP2022531387A (ja) | 2022-07-06 |
| JP2022531387A5 true JP2022531387A5 (https=) | 2023-05-12 |
| JP7716988B2 JP7716988B2 (ja) | 2025-08-01 |
Family
ID=70847527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021564994A Active JP7716988B2 (ja) | 2019-05-03 | 2020-05-01 | Ｃｄ８０細胞外ドメイン－ｆｃ融合タンパク質を含む医薬製剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220227834A1 (https=) |
| EP (1) | EP3963079A1 (https=) |
| JP (1) | JP7716988B2 (https=) |
| AR (1) | AR118853A1 (https=) |
| AU (1) | AU2020270395A1 (https=) |
| CA (1) | CA3136831A1 (https=) |
| MX (1) | MX2021013272A (https=) |
| TW (1) | TW202108126A (https=) |
| WO (1) | WO2020227062A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10273281B2 (en) | 2015-11-02 | 2019-04-30 | Five Prime Therapeutics, Inc. | CD80 extracellular domain polypeptides and their use in cancer treatment |
| KR20190139216A (ko) | 2017-04-28 | 2019-12-17 | 파이브 프라임 테라퓨틱스, 인크. | Cd80 세포외 도메인 폴리펩티드를 이용한 치료 방법 |
| US12589132B2 (en) | 2019-02-22 | 2026-03-31 | Five Prime Therapeutics, Inc. | CD80 extracellular domain Fc fusion proteins for treating PD-L1 negative tumors |
| WO2026062544A1 (en) * | 2024-09-23 | 2026-03-26 | Pfizer Inc. | Sirp alpha fusion protein formulation |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| US10273281B2 (en) | 2015-11-02 | 2019-04-30 | Five Prime Therapeutics, Inc. | CD80 extracellular domain polypeptides and their use in cancer treatment |
| US11306144B2 (en) * | 2017-08-25 | 2022-04-19 | Five Prime Therapeutics, Inc. | B7-H4 antibodies and methods of use thereof |
-
2020
- 2020-05-01 EP EP20728297.1A patent/EP3963079A1/en active Pending
- 2020-05-01 US US17/608,546 patent/US20220227834A1/en active Pending
- 2020-05-01 WO PCT/US2020/030946 patent/WO2020227062A1/en not_active Ceased
- 2020-05-01 CA CA3136831A patent/CA3136831A1/en active Pending
- 2020-05-01 MX MX2021013272A patent/MX2021013272A/es unknown
- 2020-05-01 JP JP2021564994A patent/JP7716988B2/ja active Active
- 2020-05-01 AU AU2020270395A patent/AU2020270395A1/en active Pending
- 2020-05-04 AR ARP200101262A patent/AR118853A1/es unknown
- 2020-05-04 TW TW109114796A patent/TW202108126A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7461449B2 (ja) | 治療用ｒｎａ | |
| JP2022531387A5 (https=) | ||
| US12226480B2 (en) | Combination drug including TLR7 agonist | |
| CN106459218B (zh) | 新的重组双功能融合蛋白、其制剂和用途 | |
| CA3239730A1 (en) | Stat3 degraders and uses thereof | |
| AU2019305857B2 (en) | Drug combination of quinoline derivative and antibody | |
| EP4043492A1 (en) | Antibodies specific to human poliovirus receptor (pvr) | |
| JP2020520640A5 (https=) | ||
| UA101945C2 (uk) | Лікування злоякісного новоутворення за допомогою бевацизумабу | |
| RS57492B1 (sr) | Stabilne formulacije antitela za humani receptor programirane smrti pd-1 i srodni tretmani | |
| US20210379106A1 (en) | Oxabicycloheptanes for enhancing car t cell function | |
| KR20220044521A (ko) | 인터페론계 질환 치료 방법 | |
| TW201536319A (zh) | 抗腫瘤劑及抗腫瘤效果增強劑 | |
| JP2023503050A (ja) | 免疫モジュレーター | |
| KR20220088868A (ko) | 면역조정제 | |
| WO2017045595A1 (zh) | 环二核苷酸cGAMP联合贝伐珠单抗在抗肿瘤中的应用 | |
| TWI832069B (zh) | 用於預防或治療癌症且含有萘醌系化合物及免疫檢查點抑制劑作為活性成分的藥學組成物 | |
| KR20230157947A (ko) | 암 재발 방지를 위한 방법 및 약제학적 조합 | |
| EP4115902A1 (en) | Combined use of ctb006 and ponatinib | |
| KR20230157313A (ko) | 인터페론-기반 암 치료 방법 및 약제학적 조합 | |
| CN114796469A (zh) | 芦丁类化合物与靶向nkg2d配体的car-t细胞联合制备治疗恶性肿瘤的药物 | |
| EP4681780A1 (en) | Immunocytokine for cancer treatment | |
| CN114796468A (zh) | 吉西他滨类化合物与靶向nkg2d配体的car-t细胞联合制备治疗恶性肿瘤的药物 | |
| WO2026017820A1 (en) | Fusion protein for cancer treatment | |
| KR20260020411A (ko) | 세포독성 제제에 접합된 인슐린 유사 성장 인자 1 수용체 리간드를 이용한 igf-1r 관련 소아암의 치료 방법 |